Zogenix To Present SUMAVEL(R) DosePro(TM) Phase 4 Results At American Academy Of Neurology

SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL ^® DosePro™ (sumatriptan injection) Needle-free Delivery System will be presented in two posters at the 63 ^rd Annual Meeting of the American Academy of Neurology (AAN), to be held April 9 – 16, 2011 at the Hawaii Convention Center, Honolulu, HI. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com .

The Phase 4 open-label, multicenter U.S. study evaluated overall satisfaction, confidence and preference for SUMAVEL DosePro in treating multiple migraine attacks in more than 200 adult patients diagnosed with migraine and currently taking triptan therapy. Efficacy, including onset and sustained duration of pain relief/freedom from pain, and tolerability of therapy with SUMAVEL DosePro were also measured.

Title:	Improved Treatment Satisfaction and Confidence Among Current Triptan Users Trying SUMAVEL® DosePro™ (needle-free subcutaneous sumatriptan) for Up to 4 Migraine Attacks
Authors:	Cady R, Aurora SK, Brandes JL, Rothrock J, Myers JA, Fox AW, Farr SJ
Date & Time:	Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number:	NO P05.275
Title:	Multiple-Attack Efficacy and Tolerability of SUMAVEL ® DosePro™ (needle-free subcutaneous sumatriptan) Among Current Triptan Users
Authors:	Brandes JL, Rothrock J, Cady R, Aurora SK, Myers JA, Fox AW, Farr SJ
Date & Time:	Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number:	NO P05.283

Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010 for the acute treatment of migraine and cluster headache.

1 2 3 Next › Last »